Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Permanent fixes = overpriced. Temporary relief with side effects = underpriced. Dont blame big Pharma. Dont blame insurance companies. Blame every person who pays these companies & says 'that's just how it is.' Everyone is free to make their own choices, except those babies.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 3. in PT

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

A $2 Million Drug Is About to Hit the MarketA new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price drugs and how insurers pay for it. This should be classified as a human rights violation. I'll take two, please. I don't believe $2 Million is justified. It is Medical Extortion, nothing more!
Fonte: WSJ - 🏆 98. / 63 Consulte Mais informação »